[Asia Economy Reporter Hyunseok Yoo] Cellid announced on the 15th that on the 11th, Hong Nam-ki, Deputy Prime Minister and Minister of Economy and Finance, visited Cellid’s product development research center and vaccine and cell gene therapy GMP center located in Seongnam-si, Gyeonggi-do.
Deputy Prime Minister Hong encouraged the employees, saying, “Production facilities for securing vaccine sovereignty and stable vaccine supply are very important factors to overcome the COVID-19 crisis situation. I would like to express my gratitude to the employees who are working hard on vaccine development even during the Lunar New Year holiday.”
Kang Chang-yul, CEO of Cellid, said, “All employees are doing their best to commercialize the COVID-19 vaccine as soon as possible.”
In addition, the company explained that they proposed various government-level supports such as exercising flexibility in regulatory approval reviews, establishing emergency use authorization requirements, and supporting large-scale clinical trial costs to accelerate the development of the COVID-19 vaccine.
Cellid announced that on the 26th of last month, it completed low-dose administration in Phase 1 clinical trials of the adenovirus vector-based COVID-19 preventive vaccine ‘AdCLD-CoV19’ currently underway and has started registering subjects for the medium-dose group. Recently, it was selected as the lead institution for vaccine development in the ‘3rd COVID-19 Therapeutics and Vaccine Clinical Support Public Offering’ supported by the Ministry of Health and Welfare. They are in the process of signing an agreement to support the Phase 1/2a clinical trials of ‘AdCLD-CoV19’.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
